Apnimed's July 2026 S-1 filing, targeting an IPO valuation up to $608 million via 10 million shares priced at $14–$16, anchors trader sentiment for the post-IPO closing market cap. This aligns with the leading $600–720 million bin at 50.5% implied probability, following a prior private Series D-1 valuation near $428 million. FDA acceptance of the AD109 NDA on July 14—with a February 2027 PDUFA date—supports launch funding needs, yet closely matched odds across $480–960 million+ ranges reflect uncertainty in final pricing amid biotech IPO conditions, overallotment options, and post-offering trading dynamics. Key catalysts include near-term roadshow feedback and broader risk appetite for clinical-stage assets.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour<$480M 50%
$480M-$600M 50%
$600M-$720M 50%
$720M-$840M 50%
NOUVEAU
NOUVEAU
30 juil. 2026
<$480M
50%
$480M-$600M
50%
$600M-$720M
50%
$720M-$840M
50%
$840M-$960M
50%
$960M+
50%
No IPO before October 2026
50%
<$480M 50%
$480M-$600M 50%
$600M-$720M 50%
$720M-$840M 50%
NOUVEAU
NOUVEAU
30 juil. 2026
<$480M
$20 Vol.
50%
$480M-$600M
$0 Vol.
50%
$600M-$720M
$0 Vol.
50%
$720M-$840M
$0 Vol.
50%
$840M-$960M
$0 Vol.
50%
$960M+
$0 Vol.
50%
No IPO before October 2026
$0 Vol.
50%
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed's July 2026 S-1 filing, targeting an IPO valuation up to $608 million via 10 million shares priced at $14–$16, anchors trader sentiment for the post-IPO closing market cap. This aligns with the leading $600–720 million bin at 50.5% implied probability, following a prior private Series D-1 valuation near $428 million. FDA acceptance of the AD109 NDA on July 14—with a February 2027 PDUFA date—supports launch funding needs, yet closely matched odds across $480–960 million+ ranges reflect uncertainty in final pricing amid biotech IPO conditions, overallotment options, and post-offering trading dynamics. Key catalysts include near-term roadshow feedback and broader risk appetite for clinical-stage assets.
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Marché ouvert : Jul 29, 2026, 6:20 PM ET
Volume
$20Date de fin
31 juil. 2026Marché ouvert
Jul 29, 2026, 6:20 PM ETResolver
0x69c47De9D...This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Apnimed's July 2026 S-1 filing, targeting an IPO valuation up to $608 million via 10 million shares priced at $14–$16, anchors trader sentiment for the post-IPO closing market cap. This aligns with the leading $600–720 million bin at 50.5% implied probability, following a prior private Series D-1 valuation near $428 million. FDA acceptance of the AD109 NDA on July 14—with a February 2027 PDUFA date—supports launch funding needs, yet closely matched odds across $480–960 million+ ranges reflect uncertainty in final pricing amid biotech IPO conditions, overallotment options, and post-offering trading dynamics. Key catalysts include near-term roadshow feedback and broader risk appetite for clinical-stage assets.
This market will resolve based on Apnimed's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 31 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$20Date de fin
31 juil. 2026Marché ouvert
Jul 29, 2026, 6:20 PM ETResolver
0x69c47De9D...Apnimed's July 2026 S-1 filing, targeting an IPO valuation up to $608 million via 10 million shares priced at $14–$16, anchors trader sentiment for the post-IPO closing market cap. This aligns with the leading $600–720 million bin at 50.5% implied probability, following a prior private Series D-1 valuation near $428 million. FDA acceptance of the AD109 NDA on July 14—with a February 2027 PDUFA date—supports launch funding needs, yet closely matched odds across $480–960 million+ ranges reflect uncertainty in final pricing amid biotech IPO conditions, overallotment options, and post-offering trading dynamics. Key catalysts include near-term roadshow feedback and broader risk appetite for clinical-stage assets.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes